October 1, 2019
Takara Bio has withdrawn its submission in Japan for conditional, time-limited approval of its oncolytic virus canerpaturev (C-REV) for the treatment of melanoma due to discrepancies in the interpretation of requirements. According to its statement released on September 27, the...read more